Actively Recruiting
TACE Combined Surgery for the Resectable Huge HCC
Led by Sun Yat-sen University · Updated on 2025-04-03
326
Participants Needed
1
Research Sites
51 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Huge hepatocellular carcinoma (HCC) is defined as a tumor with a maximum diameter greater than 10 cm. With advancements in surgical techniques, hepatectomy can be performed safely in some patients with huge HCC without vascular invasion or distant metastasis and with preserved liver function. The high risk of recurrence after surgery is another challenge for surgeons. Neoadjuvant TACE has been shown to improve the clinical outcomes of patients with HCC, especially those with a high risk of recurrence, such as those with multinodular tumors, large tumors, and tumor thrombus. The present multicenter study aimed to evaluate the efficacy of neoadjuvant TACE in patients with huge HCC who underwent liver resection.
CONDITIONS
Official Title
TACE Combined Surgery for the Resectable Huge HCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical or pathological diagnosis of primary hepatocellular carcinoma (HCC)
- Tumor diameter greater than 10 cm on imaging before enrollment
- Age between 18 and 75 years
- No macrovascular invasion or spread of cancer outside the liver
- Liver resection planned with complete tumor removal and adequate remaining liver volume
- Albumin-bilirubin (ALBI) grade I or II
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Hemoglobin level at least 8.5 g/dL
- Total bilirubin level no higher than 30 mmol/L
- Alanine transaminase (ALT) and aspartate aminotransferase (AST) levels up to 5 times the upper normal limit
- Serum creatinine level no higher than 1.5 times the upper normal limit
- Prothrombin time no longer than 18 seconds or international normalized ratio less than 1.7
You will not qualify if you...
- Hepatocellular carcinoma with macrovascular invasion or spread outside the liver
- Tumor diameter 10 cm or less on imaging
- Recurrent hepatocellular carcinoma
- Serious other medical conditions
- Portal hypertension, including esophageal varices or enlarged spleen with low platelet count (below 109/L)
- Heart rhythm problems needing anti-arrhythmic treatment
- Incomplete medical data or lost to follow-up within three months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA general hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
Q
Qunfang Zhou, MD
CONTACT
F
Feng Duan, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here